Background: Radiotherapy can provide symptomatic relief in the palliativemanagement of patients with metastatic prostate cancer (mPC) however this would not usually be offered to those patients with a prognosis of less than three months. This study aims to determine the predictive value of a set of routinely collected parameters with respect to prognosis in these patients. Methods: A retrospective analysis of 101 patients with metastatic prostatecancer who received palliative radiotherapy between 2009 and 2012 wasperformed. The variables measured were haemoglobin (Hb;g/dl), age (years), prostate-specific antigen (PSA;ng/ ml), PSA doubling time (months),neutrophil:lymphocyte ratio (NLR) and albumin (g/ L). Each variable wasmeasured within the 3 months preceding radiotherapy. The dataset was split randomly into a training set (n = 59) and a validation set (n = 29).
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Overall survival univariate cox models were performed in the training set using each of the variables above. Those variables with a p-value < 0.10 were then included in an overall survival multivariate cox model performed in the training set. The overall survival multivariate cox model was then applied to the validation set. For each patient in the validation set a prognostic score was obtained and patients were classified by the event of interest (death within 3 months of radiotherapy). 
